A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations.

Martin H VossCinta HierroRebecca S HeistJames M ClearyFunda Meric-BernstamJosep TaberneroFilip JankuLeena GandhiA John IafrateDarrell R BorgerNobuya IshiiYouyou HuYulia KirpichevaValerie Nicolas-MetralAnna Pokorska-BocciAnne Vaslin ChessexClaudio ZannaKeith T FlahertyJose Baselga

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

Preliminary efficacy was encouraging and tolerability acceptable up to 80 mg/day, which is now used in an extension part of the study.

Keyphrases

open label
squamous cell carcinoma
genome wide
radiation therapy
study protocol
phase ii
copy number
phase iii